These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22471290)

  • 1. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes.
    Rocca B; Santilli F; Pitocco D; Mucci L; Petrucci G; Vitacolonna E; Lattanzio S; Mattoscio D; Zaccardi F; Liani R; Vazzana N; Del Ponte A; Ferrante E; Martini F; Cardillo C; Morosetti R; Mirabella M; Ghirlanda G; Davì G; Patrono C
    J Thromb Haemost; 2012 Jul; 10(7):1220-30. PubMed ID: 22471290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
    Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
    Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target.
    Pascale S; Petrucci G; Dragani A; Habib A; Zaccardi F; Pagliaccia F; Pocaterra D; Ragazzoni E; Rolandi G; Rocca B; Patrono C
    Blood; 2012 Apr; 119(15):3595-603. PubMed ID: 22234683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment.
    Pulcinelli FM; Biasucci LM; Riondino S; Giubilato S; Leo A; Di Renzo L; Trifirò E; Mattiello T; Pitocco D; Liuzzo G; Ghirlanda G; Crea F
    Eur Heart J; 2009 May; 30(10):1279-86. PubMed ID: 19346231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
    Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
    J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
    Capodanno D; Patel A; Dharmashankar K; Ferreiro JL; Ueno M; Kodali M; Tomasello SD; Capranzano P; Seecheran N; Darlington A; Tello-Montoliu A; Desai B; Bass TA; Angiolillo DJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):180-7. PubMed ID: 21386092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.
    Guthikonda S; Lev EI; Patel R; DeLao T; Bergeron AL; Dong JF; Kleiman NS
    J Thromb Haemost; 2007 Mar; 5(3):490-6. PubMed ID: 17319904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human pharmacology of naproxen sodium.
    Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
    Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
    Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.
    Anzellotti P; Capone ML; Jeyam A; Tacconelli S; Bruno A; Tontodonati P; Di Francesco L; Grossi L; Renda G; Merciaro G; Di Gregorio P; Price TS; Garcia Rodriguez LA; Patrignani P
    Arthritis Rheum; 2011 Mar; 63(3):850-9. PubMed ID: 21360514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.
    Smith JP; Haddad EV; Taylor MB; Oram D; Blakemore D; Chen Q; Boutaud O; Oates JA
    Hypertension; 2012 Mar; 59(3):719-25. PubMed ID: 22311905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
    Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
    Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.
    Patrignani P; Filabozzi P; Patrono C
    J Clin Invest; 1982 Jun; 69(6):1366-72. PubMed ID: 7045161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.
    Pettinella C; Romano M; Stuppia L; Santilli F; Liani R; Davì G
    Thromb Haemost; 2009 Apr; 101(4):687-90. PubMed ID: 19350112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.
    Dragani A; Pascale S; Recchiuti A; Mattoscio D; Lattanzio S; Petrucci G; Mucci L; Ferrante E; Habib A; Ranelletti FO; Ciabattoni G; Davì G; Patrono C; Rocca B
    Blood; 2010 Feb; 115(5):1054-61. PubMed ID: 19887674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals.
    Kimura Y; Takano K; Satoh K; Aida K; Kobayashi T; Ozaki Y
    Clin Appl Thromb Hemost; 2014 Sep; 20(6):629-36. PubMed ID: 23677911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.
    Rocca B; Tosetto A; Betti S; Soldati D; Petrucci G; Rossi E; Timillero A; Cavalca V; Porro B; Iurlo A; Cattaneo D; Bucelli C; Dragani A; Di Ianni M; Ranalli P; Palandri F; Vianelli N; Beggiato E; Lanzarone G; Ruggeri M; Carli G; Elli EM; Carpenedo M; Randi ML; Bertozzi I; Paoli C; Specchia G; Ricco A; Vannucchi AM; Rodeghiero F; Patrono C; De Stefano V
    Blood; 2020 Jul; 136(2):171-182. PubMed ID: 32266380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.
    Capone ML; Sciulli MG; Tacconelli S; Grana M; Ricciotti E; Renda G; Di Gregorio P; Merciaro G; Patrignani P
    J Am Coll Cardiol; 2005 Apr; 45(8):1295-301. PubMed ID: 15837265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
    Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
    Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.
    Jakubowski JA; Stampfer MJ; Vaillancourt R; Faigel D; Deykin D
    J Lab Clin Med; 1986 Dec; 108(6):616-21. PubMed ID: 3097223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.